IRADIMED CORP (IRMD) Form 8-K — Jul 31, 2026
Iradimed reported second quarter 2026 revenue of $20.5 million, a 0.5% increase from the prior year, while GAAP diluted EPS fell 9% to $0.41 due to startup costs associated with its new 3870 pump platform. Despite the earnings decline, the company noted that domestic monitor unit bookings set a record and gross margins are expected to improve in the second half of the year as production ramps up. Management reaffirmed its full-year 2026 guidance for revenue of $91.0 million to $96.0 million and GAAP EPS of $1.90 to $2.05, indicating confidence in the product transition.
Key figures
- Eps
- 0.41
- Revenue
- 20466000
- Guidance
- Q3 2026 Revenue $23.0M-$24.5M; Full Year 2026 Revenue $91.0M-$96.0M; Full Year 2026 GAAP EPS $1.90-$2.05
- Net Income
- 5218000
- Cash Position
- 59080000
- Shares Outstanding
- 12872000
- Quarterly dividend
- 0.20
- Gross profit margin
- 74%
Price after filing
Close on the filing date to close N calendar days later (from $94.26). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.